Article

A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistance

2026-04-03

Abstract excerpt

Tyrosine Kinase inhibitors (TKIs) are widely used as effective chemotherapeutic agents for treating patients with EGFR-mutated NSCLC. Unfortunately, after treatment, patients eventually develop resistance to TKI therapy. The most common resistance mechanism for the TKI Osimertinib is the overexpression of the MET Proto-Oncogene, Receptor Tyrosine Kinase (MET). We previously demonstrated that miR-411-5p A-to-I edit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ecc1fe86-2d8d-5df5-8702-c635ff0f1f56
DOI: 10.64898/2026.03.31.715663

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A multi-omics approach to identify the impact of miR-411ed on NSCLC TKI resistanceDOI 10.64898/2026.03.31.715663Read

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancerSemantic proximity Read

Elevated Exosome-derived Mirnas Predict Osimertinib Resistance in Non-small Cell Lung CancerSemantic proximity Read

Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.Semantic proximity Read

A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLCSemantic proximity Read

Exosomes miR-184 and miR-3913-5p are involved in Osimertinib resistance in non-small cell lung cancer patients with exon 21 L858R mutationSemantic proximity Read

Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.Semantic proximity Read

Global proteome and phosphoproteome alterations in third generation EGFR TKI resistance reveal drug targets to circumvent resistanceSemantic proximity Read

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung CancerSemantic proximity Read

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity Read

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent ResistanceSemantic proximity Read

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI.Semantic proximity Read

STK11 genetic alterations in metastatic EGFR mutant lung cancerSemantic proximity Read